Latest Insider Transactions at Myo Kardia Inc (MYOK)
This section provides a real-time view of insider transactions for Myo Kardia Inc (MYOK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MyoKardia Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MyoKardia Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2020
|
Denelle J Waynick Chief Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,000
-100.0%
|
-
|
|
Nov 17
2020
|
Wendy L Yarno Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,508
-100.0%
|
-
|
|
Nov 17
2020
|
Anastasios Gianakakos President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
605,668
-100.0%
|
-
|
|
Nov 17
2020
|
Anastasios Gianakakos President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
141,405
-100.0%
|
-
|
|
Nov 17
2020
|
Mary B Cranston Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Nov 17
2020
|
Kimberly J Popovits Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Nov 17
2020
|
Mark L Perry Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
29,508
-100.0%
|
-
|
|
Nov 17
2020
|
Jake Bauer Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
90,209
-100.0%
|
-
|
|
Nov 17
2020
|
William Fairey EVP, Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,199
-100.0%
|
-
|
|
Nov 17
2020
|
Sunil Agarwal Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Nov 17
2020
|
Taylor C. Harris Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,559
-100.0%
|
-
|
|
Nov 17
2020
|
Robert Scott Mc Dowell Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
36,616
-100.0%
|
-
|
|
Nov 17
2020
|
David P Meeker Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Feb 13
2019
|
Sanofi > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,168,899
-100.0%
|
$154,249,263
$37.66 P/Share
|
|
May 25
2018
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+3.47%
|
$7,350,000
$49.0 P/Share
|
|
Mar 07
2018
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-69.32%
|
-
|
|
Jan 03
2018
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
816,326
-54.55%
|
$34,285,692
$42.0 P/Share
|
|
Dec 06
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-40.94%
|
-
|
|
Sep 28
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-29.05%
|
-
|
|
Sep 26
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
400,000
-5.49%
|
$17,200,000
$43.0 P/Share
|
|
Sep 25
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
201,400
-2.69%
|
$8,660,200
$43.0 P/Share
|
|
Sep 11
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,000
-25.76%
|
$880,000
$44.25 P/Share
|
|
Sep 08
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
201,250
-1.31%
|
$8,251,250
$41.7 P/Share
|
|
Aug 14
2017
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
350,000
+8.01%
|
$12,250,000
$35.5 P/Share
|
|
Oct 03
2016
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
450,000
+10.93%
|
$6,750,000
$15.0 P/Share
|
|
Nov 03
2015
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
900,000
+21.85%
|
$9,000,000
$10.0 P/Share
|
|
Nov 03
2015
|
Sanofi > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,318,899
+50.0%
|
-
|